Cargando…
Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small c...
Autores principales: | XUE, XINYING, XUE, QINGLIANG, LIU, YUXIA, PAN, LEI, WANG, KAIFEI, ZHANG, LINA, WANG, NA, YANG, BING, WANG, JIANXIN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678659/ https://www.ncbi.nlm.nih.gov/pubmed/23761825 http://dx.doi.org/10.3892/ol.2013.1212 |
Ejemplares similares
-
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016) -
MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN
por: Xue, Xinying, et al.
Publicado: (2016) -
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
por: Kawata, Toshio, et al.
Publicado: (2019) -
Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022) -
Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
por: Tian, Qing, et al.
Publicado: (2011)